US heparin overdoses "not preventable" by IT

20 July 2008

Accidental overdoses of the blood thinner heparin which were given to 17 infants at a Texas, USA, hospital might not have been avoidable by the adoption of a computer physician order entry system. The error, which follows similar reports in other parts of the country (Marketletters passim), was allegedly made by a pharmacist, but the type of intravenous procedure used would not normally be part of a physician's orders, according to Dennis Tribble, the chairman of the pharmacy-informatics section of the American Society of Health System Pharmacists.

Baxter Healthcare, a leading supplier of heparin in the USA, has already changed the label design on its packaging, making it easier to distinguish between different dosages of the drug. However, a UK-based nursing expert told the Marketletter that the best practice for IV treatments would require two staff members to double-check that the correct drug and amount was administered. This has been cut down to one person in some clinical environments, for example in the UK. In US medical centers where accidental heparin overdoses were given, reports have not confirmed the number of staff required for verifying IV dosages.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight